...
search icon
smmt-img

Summit Therapeutics PLC, Common Stock

SMMT

NMQ

$27.35

+$2.13

(8.45%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$18.16B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
4.62M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-0.46
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.1 L
$33.89 H
$27.35

About Summit Therapeutics PLC, Common Stock

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. Its lead development candidate, ivonescimab, is a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and is also in Phase III clinical trials for the treatment of non-small lung cancer. The company has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. Summit Therapeutics Inc. was founded in 2003 and is headquartered in Miami, Florida. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameSMMTSectorS&P500
1-Week Return11.09%-1.91%-4.4%
1-Month Return32.19%-8.22%-10.77%
3-Month Return16.28%-5.01%-15.29%
6-Month Return32.83%-10.62%-11.9%
1-Year Return683.67%-3.17%2.9%
3-Year Return1274.37%1.04%20.61%
5-Year Return592.41%37.23%84.18%
10-Year Return148.64%81.65%144.64%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue860.00K1.81M704.29K--[{"date":"2020-12-31","value":47.54,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":38.93,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue--2.51M2.05M15.01M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":16.75,"profit":true},{"date":"2023-12-31","value":13.66,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit860.00K1.81M(1.81M)(2.05M)(15.01M)[{"date":"2020-12-31","value":47.54,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-100.04,"profit":false},{"date":"2023-12-31","value":-113.32,"profit":false},{"date":"2024-12-31","value":-829.57,"profit":false}]
Gross Margin100.00%100.00%(256.95%)--[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-256.95,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses53.19M88.00M64.28M87.69M211.30M[{"date":"2020-12-31","value":25.17,"profit":true},{"date":"2021-12-31","value":41.64,"profit":true},{"date":"2022-12-31","value":30.42,"profit":true},{"date":"2023-12-31","value":41.5,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(53.19M)(86.19M)(72.09M)(89.74M)313.00K[{"date":"2020-12-31","value":-16994.57,"profit":false},{"date":"2021-12-31","value":-27535.46,"profit":false},{"date":"2022-12-31","value":-23031.63,"profit":false},{"date":"2023-12-31","value":-28669.65,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Total Non-Operating Income/Expense(14.26M)(2.70M)(23.55M)(532.20M)(216.85M)[{"date":"2020-12-31","value":-1426361900,"profit":false},{"date":"2021-12-31","value":-269700000,"profit":false},{"date":"2022-12-31","value":-2354953800,"profit":false},{"date":"2023-12-31","value":-53219600000,"profit":false},{"date":"2024-12-31","value":-21684800000,"profit":false}]
Pre-Tax Income(52.91M)(88.60M)(78.78M)(615.87M)(221.31M)[{"date":"2020-12-31","value":-5291000000,"profit":false},{"date":"2021-12-31","value":-8860200000,"profit":false},{"date":"2022-12-31","value":-7878200000,"profit":false},{"date":"2023-12-31","value":-61587400000,"profit":false},{"date":"2024-12-31","value":-22131500000,"profit":false}]
Income Taxes(213.00K)(2.46M)(4.40M)(946.00K)(221.31M)[{"date":"2020-12-31","value":-21300000,"profit":false},{"date":"2021-12-31","value":-245500000,"profit":false},{"date":"2022-12-31","value":-440100000,"profit":false},{"date":"2023-12-31","value":-94600000,"profit":false},{"date":"2024-12-31","value":-22131500000,"profit":false}]
Income After Taxes(52.70M)(86.15M)(74.38M)(614.93M)-[{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(52.70M)(88.60M)(78.78M)(614.93M)(221.29M)[{"date":"2020-12-31","value":-5269700000,"profit":false},{"date":"2021-12-31","value":-8860200000,"profit":false},{"date":"2022-12-31","value":-7878200000,"profit":false},{"date":"2023-12-31","value":-61492800000,"profit":false},{"date":"2024-12-31","value":-22128800000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(52.70M)(86.15M)(74.38M)(614.93M)(221.31M)[{"date":"2020-12-31","value":-5269700000,"profit":false},{"date":"2021-12-31","value":-8614700000,"profit":false},{"date":"2022-12-31","value":-7438100000,"profit":false},{"date":"2023-12-31","value":-61492800000,"profit":false},{"date":"2024-12-31","value":-22131500000,"profit":false}]
EPS (Diluted)(3.73)(3.68)(0.62)(1.54)(0.29)[{"date":"2020-12-31","value":-372.88,"profit":false},{"date":"2021-12-31","value":-367.64,"profit":false},{"date":"2022-12-31","value":-62.15,"profit":false},{"date":"2023-12-31","value":-153.8,"profit":false},{"date":"2024-12-31","value":-29.33,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

SMMT
Cash Ratio 9.88
Current Ratio 10.15

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

SMMT
ROA (LTM) -41.31%
ROE (LTM) -94.90%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

SMMT
Debt Ratio Lower is generally better. Negative is bad. 0.11
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.89

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

SMMT
Trailing PE NM
Forward PE NM
P/S (TTM) 753.90
P/B 46.70
Price/FCF NM
EV/R 6425.28
EV/Ebitda NM
PEG NM

FAQs

What is Summit Therapeutics PLC share price today?

Summit Therapeutics PLC (SMMT) share price today is $27.35

Can Indians buy Summit Therapeutics PLC shares?

Yes, Indians can buy shares of Summit Therapeutics PLC (SMMT) on Vested. To buy Summit Therapeutics PLC from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SMMT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Summit Therapeutics PLC be purchased?

Yes, you can purchase fractional shares of Summit Therapeutics PLC (SMMT) via the Vested app. You can start investing in Summit Therapeutics PLC (SMMT) with a minimum investment of $1.

How to invest in Summit Therapeutics PLC shares from India?

You can invest in shares of Summit Therapeutics PLC (SMMT) via Vested in three simple steps:

  • Click on Sign Up or Invest in SMMT stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Summit Therapeutics PLC shares
What is Summit Therapeutics PLC 52-week high and low stock price?

The 52-week high price of Summit Therapeutics PLC (SMMT) is $33.89. The 52-week low price of Summit Therapeutics PLC (SMMT) is $2.1.

What is Summit Therapeutics PLC price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Summit Therapeutics PLC (SMMT) is 46.70

What is the Market Cap of Summit Therapeutics PLC?

The market capitalization of Summit Therapeutics PLC (SMMT) is $18.16B

What is Summit Therapeutics PLC’s stock symbol?

The stock symbol (or ticker) of Summit Therapeutics PLC is SMMT

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top